{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:04:15Z","timestamp":1773299055214,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,2,27]],"date-time":"2008-02-27T00:00:00Z","timestamp":1204070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> The aim of this post hoc analysis was to evaluate whether treatment of patients with atopic dermatitis (AD) with pimecrolimus cream 1% can decrease the development of flares necessitating the use of a topical corticosteroid on the face and thus reduce the need for use of topical corticosteroids in this sensitive skin area.<\/jats:p><jats:p><jats:bold>Patients and methods\u2002<\/jats:bold> In a controlled, double\u2010blind, multicentre study, 140 patients, aged 2 to 17\u00a0years, with facial involvement and mild to moderate disease after treatment of the initial flare with prednicarbate 0.25% cream were randomized to an intermittent treatment with pimecrolimus cream 1% twice daily or vehicle for 24\u00a0weeks. If a flare occurred, defined as an exacerbation (unacceptable severity of itching\/scratching or onset of oozing) not controlled by study medication, patients were treated with prednicarbate 0.25% cream instead.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Patients in the vehicle group needed prednicarbate treatment on the face on 20.7% of the days vs. 11.7% of the study days in the pimecrolimus group (<jats:italic>P\u00a0=<\/jats:italic>\u00a00.0024). Fifty per cent of patients in the pimecrolimus group had no flare on the face during the treatment period compared with 37.5% of patients in the vehicle group (<jats:italic>P\u00a0=<\/jats:italic>\u00a00.012). The median time to first flare in pimecrolimus\u2010treated patients was twice as long as in patients receiving vehicle (138 vs. 68\u00a0days, <jats:italic>P<\/jats:italic>\u00a0=\u00a00.01). Three adverse events (one case of skin burning) suspected to be related to use of the study medication were reported for three patients (3.9%) in the pimecrolimus group.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Long\u2010term intermittent treatment of facial AD in children and adolescents with pimecrolimus cream 1% does significantly reduce the need for topical corticosteroids.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2008.02586.x","type":"journal-article","created":{"date-parts":[[2008,2,27]],"date-time":"2008-02-27T16:22:48Z","timestamp":1204129368000},"page":"718-721","source":"Crossref","is-referenced-by-count":41,"title":["Long\u2010term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease"],"prefix":"10.1111","volume":"22","author":[{"given":"T","family":"Zuberbier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Br\u00e4utigam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,2,27]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262050-00007"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.09.016"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0906-6705.2004.00269.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2003.00692.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.1.e2"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1159\/000065863"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2002.126500"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1159\/000107627"},{"key":"e_1_2_7_10_2","first-page":"440","article-title":"Predisposition to sensitive skin and atopic eczema","volume":"78","author":"Cork MJ","year":"2005","journal-title":"Community Practitioner"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.04.030"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.01.010"},{"key":"e_1_2_7_13_2","first-page":"AB3","article-title":"Interaction of topical corticosteroids and pimecrolimus with the skin barrier. implications for efficacy and safety of treatment for atopic dermatitis","volume":"54","author":"Cork M","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_7_14_2","first-page":"616","article-title":"Guidelines of care for the use of topical glucocorticosteroids","volume":"35","author":"Drake LA","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04076.x"},{"issue":"2","key":"e_1_2_7_16_2","first-page":"AB","article-title":"Belgian drug utilization study of pimecrolimus cream 1% in routine practice in atopic dermatitis","volume":"56","author":"De Backer M","year":"2007","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2008.02586.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2008.02586.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T05:06:30Z","timestamp":1697000790000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2008.02586.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,27]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1111\/j.1468-3083.2008.02586.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2008.02586.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,27]]}}}